SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cohance Lifesciences - Quaterly Results

13 Feb 2026 Evaluate
The sales slipped to Rs. 4815.80 millions for the December 2025 quarter as against Rs. 6533.50 millions during the year-ago period.A big decline of -69.26% was reported for the quarter ended December 2025 to Rs. 472.90  millions from Rs. 1538.60 millions of corresponding previous quarter.Operating Profit reported a sharp decline to 1089.00 millions from 2542.30 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 4815.80 6533.50 -26.29 14629.50 17358.60 -15.72 10935.10 10513.50 4.01
Other Income 61.20 214.80 -71.51 455.20 566.50 -19.65 539.80 566.10 -4.65
PBIDT 1089.00 2542.30 -57.16 3833.60 6180.90 -37.98 4165.50 4624.70 -9.93
Interest 52.50 100.80 -47.92 172.90 297.00 -41.78 80.00 74.50 7.38
PBDT 987.90 2441.50 -59.54 3531.10 5883.90 -39.99 4085.50 4550.20 -10.21
Depreciation 333.60 380.90 -12.42 959.20 1039.30 -7.71 572.00 546.00 4.76
PBT 654.30 2060.60 -68.25 2571.90 4844.60 -46.91 3513.50 4004.20 -12.25
TAX 181.40 522.00 -65.25 630.40 1160.50 -45.68 796.40 1039.50 -23.39
Deferred Tax 54.80 -177.00 -130.96 60.20 -245.20 -124.55 -127.30 65.90 -293.17
PAT 472.90 1538.60 -69.26 1941.50 3684.10 -47.30 2717.10 2964.70 -8.35
Equity 382.60 254.60 50.27 382.60 254.60 50.27 254.60 254.60 0.00
PBIDTM(%) 22.61 38.91 -41.89 26.20 35.61 -26.41 38.09 43.99 -13.40

Cohance Lifesciences Share Price

360.80 -8.55 (-2.31%)
21-Apr-2026 13:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.60
Dr. Reddys Lab 1220.90
Cipla 1231.05
Zydus Lifesciences 927.40
Lupin 2324.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×